JP7612025B2 - 敗血症を治療するための薬物組成物及びその使用 - Google Patents

敗血症を治療するための薬物組成物及びその使用 Download PDF

Info

Publication number
JP7612025B2
JP7612025B2 JP2023538107A JP2023538107A JP7612025B2 JP 7612025 B2 JP7612025 B2 JP 7612025B2 JP 2023538107 A JP2023538107 A JP 2023538107A JP 2023538107 A JP2023538107 A JP 2023538107A JP 7612025 B2 JP7612025 B2 JP 7612025B2
Authority
JP
Japan
Prior art keywords
paeoniflorin
albiflorin
sepsis
group
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023538107A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504263A5 (https=
JP2024504263A (ja
Inventor
于洋
王建立
蒋春亮
王向成
李玉坤
李宝斎
張桂萍
董凱
姚小青
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianjin Chase Sun Pharmaceutical Co Ltd
Original Assignee
Tianjin Chase Sun Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Chase Sun Pharmaceutical Co Ltd filed Critical Tianjin Chase Sun Pharmaceutical Co Ltd
Publication of JP2024504263A publication Critical patent/JP2024504263A/ja
Publication of JP2024504263A5 publication Critical patent/JP2024504263A5/ja
Application granted granted Critical
Publication of JP7612025B2 publication Critical patent/JP7612025B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023538107A 2021-03-01 2021-03-23 敗血症を治療するための薬物組成物及びその使用 Active JP7612025B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110225428.6 2021-03-01
CN202110225428.6A CN112891362B (zh) 2021-03-01 2021-03-01 一种用于治疗脓毒症的药物组合物及其应用
PCT/CN2021/082244 WO2022183539A1 (zh) 2021-03-01 2021-03-23 一种用于治疗脓毒症的药物组合物及其应用

Publications (3)

Publication Number Publication Date
JP2024504263A JP2024504263A (ja) 2024-01-31
JP2024504263A5 JP2024504263A5 (https=) 2024-09-17
JP7612025B2 true JP7612025B2 (ja) 2025-01-10

Family

ID=76108370

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023538107A Active JP7612025B2 (ja) 2021-03-01 2021-03-23 敗血症を治療するための薬物組成物及びその使用

Country Status (4)

Country Link
EP (1) EP4248964A4 (https=)
JP (1) JP7612025B2 (https=)
CN (1) CN112891362B (https=)
WO (1) WO2022183539A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113413379A (zh) * 2021-06-28 2021-09-21 中国人民解放军海军军医大学第一附属医院 洋川芎内酯i在脓毒症肺损伤治疗药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190269609A1 (en) 2016-12-28 2019-09-05 Tianjin Chase Sun Pharmaceutical Co., Ltd. A multi-component injection

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1190223C (zh) * 2003-03-04 2005-02-23 天津红日药业股份有限公司 一种治疗脓毒症的中药制剂及其制备方法
CN101317893B (zh) * 2008-07-11 2011-07-20 天津红日药业股份有限公司 一种血必净口服泡腾剂
CN104546832A (zh) * 2013-10-12 2015-04-29 烟台益诺依生物医药科技有限公司 一种药物组合物在制备治疗脓毒症药物中应用
CN105181848B (zh) * 2015-09-29 2017-02-01 天津宏仁堂药业有限公司 血府逐瘀汤及胶囊的uplc指纹图谱检测方法
CN105241980B (zh) * 2015-11-12 2017-05-24 陕西步长制药有限公司 一种脑心通胶囊快速分离液相色谱检测方法
CN106950307B (zh) * 2017-03-29 2019-05-03 中国科学院上海药物研究所 一种血必净注射液中五类化合物的检测方法
CN108508107B (zh) * 2018-03-22 2021-10-08 天津中医药大学 一种同时测定血浆中血必净注射液有效成分的方法
CN108743600B (zh) * 2018-07-04 2021-03-09 天津中医药大学 一种天然药物组合物和含有该天然药物的中药组合物及其应用
CN109260214A (zh) * 2018-10-19 2019-01-25 天津红日药业股份有限公司 芍药苷类化合物在制备治疗脓毒症药物中的应用
CN109394750A (zh) * 2018-10-19 2019-03-01 天津红日药业股份有限公司 羟基红花黄色素a在制备治疗脓毒症药物中的应用
CN109709244A (zh) * 2019-02-22 2019-05-03 天津红日药业股份有限公司 一种血必净注射液苯酞内酯类成分含量测定方法
CN110632230B (zh) * 2019-09-29 2021-07-27 中国科学院上海药物研究所 一种血必净注射液中多个小分子化学成分的检测方法
CN110907576B (zh) * 2019-11-06 2022-02-11 河北医科大学 同时测定冠心静胶囊中16个活性成分含量的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190269609A1 (en) 2016-12-28 2019-09-05 Tianjin Chase Sun Pharmaceutical Co., Ltd. A multi-component injection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Hao HUANG et al.，"Identification of the major constituents in Xuebijing injection by HPLC‐ESI‐MS"，Phytochemical Analysis，2011年04月15日，Vol. 22, No. 4，p.330-338，DOI: 10.1002/pca.1284
Min JIANG et al.，"Identification of NF-κB Inhibitors in Xuebijing injection for sepsis treatment based on bioactivity-integrated UPLC-Q/TOF"，Journal of Ethnopharmacology，2013年05月，Vol. 147, No. 2，p.426-433，DOI: 10.1016/j.jep.2013.03.032

Also Published As

Publication number Publication date
EP4248964A4 (en) 2024-05-22
US20240307425A1 (en) 2024-09-19
EP4248964A1 (en) 2023-09-27
JP2024504263A (ja) 2024-01-31
WO2022183539A1 (zh) 2022-09-09
CN112891362B (zh) 2022-09-20
CN112891362A (zh) 2021-06-04

Similar Documents

Publication Publication Date Title
Wang et al. Angelica sinensis polysaccharide attenuates CCl4-induced liver fibrosis via the IL-22/STAT3 pathway
Zhu et al. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo
Tian et al. Angelicin alleviates post-trauma osteoarthritis progression by regulating macrophage polarization via STAT3 signaling pathway
CN103919854B (zh) 密蒙花及其提取物在制备药物中的应用
WO2021249420A1 (zh) 血筒素在制备抗类风湿关节炎药物中的应用
JP7612025B2 (ja) 敗血症を治療するための薬物組成物及びその使用
AU2016390488B9 (en) Application of dimethylamino micheliolide
CN106220643A (zh) 灵芝内酯d及其药物组合物与其在制药和食品中的应用
CN103083302B (zh) 丹酚酸a组合物用于制备保护缺血脑组织损伤药物的用途
CN103083297B (zh) 丹酚酸a组合物用于制备改善脑缺血后的神经功能症状药物的用途
WO2009062374A1 (fr) Utilisation pharmaceutique de liquiritigénine pour préparer un médicament destiné au traitement de maladies neurodégénératives
WO2021249402A1 (zh) 无细胞脂肪提取液对巨噬细胞极化调节与疾病治疗的作用
CN108785299A (zh) 光甘草定在制备治疗血栓性疾病药物中的应用
CN103083301B (zh) 丹酚酸a组合物用于制备预防和或治疗脑血栓药物的用途
CN103083306B (zh) 丹酚酸a组合物用于制备抑制脑组织神经元损伤或死亡药物的用途
CN103083298B (zh) 丹酚酸a组合物用于制备保护缺血脑组织损伤药物的用途
US12616709B2 (en) Pharmaceutical composition for treating sepsis and use thereof
CN111437358A (zh) 一种用于治疗痰浊瘀阻证引起的动脉粥样硬化的中药组合物
CN101269063A (zh) 表没食子儿茶素没食子酸酯在制备具有预防和治疗人乳腺癌症的产品中的应用
CN103083296B (zh) 丹酚酸a组合物用于制备保护脑血管内皮细胞药物的用途
CN104274437B (zh) A型三聚原花青素类多酚的一种药物用途
CN109045107B (zh) 一种治疗类风湿关节炎的药物及制备方法
TW201717981A (zh) 苦瓜素之萃取方法、包含苦瓜素之醫藥組成物及其用途
CN108478553A (zh) 基于血管内皮炎性损伤的炎症性病症防治药物及其应用
KR102858091B1 (ko) 안히드로이카리틴의 의약적 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240723

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240906

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241224

R150 Certificate of patent or registration of utility model

Ref document number: 7612025

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150